RARECast cover art

All Episodes

RARECast — 602 episodes

#
Title
1

Rewiring the Rare Disease Diagnostic Odyssey

2

Emerging from a Life in the Shadows

3

Fitting Big Genes into Small Vectors

4

Targeting Iron Dysregulation in the Neurodegenerative Condition MSA

5

Long Reads, Shorter Journeys

6

The Critical Role of Patient Community-Industry Partnership in Advancing a Gene Therapy

7

Capturing the Lived Experience of Rare Disease

8

Raising Awareness of Clinical Trials

9

Using AI and Longitudinal Data to Transform Rare Disease Care

10

Cutting through the Diagnostic Maze for Rare Diseases

11

How Parents Took Development of a Gene Therapy into Their Own Hands

12

Matching the Right Therapy to the Right Child with a Rare Cancer

13

From Treating Symptoms to Addressing Causes in Rare Autoimmune Diseases

14

A Mother’s Journey to Rewrite a Neurodevelopmental Disorder

15

How a Foundation Built Its Own Drug Program for an Ultra-Rare Disease

16

From Bloodletting to Breakthroughs in PV

17

When Endpoints Miss the Point

18

Reopening the Developmental Window in Rett Syndrome with a Gene Therapy

19

A Data Strategy to Capitalize on a Multi Trillion Dollar Opportunity

20

When a Gene Echoes Through a Family

21

Changing the Autoimmune Disease Playbook with RNA-Engineered CAR T Cells

22

Rewriting Rare Disease R&D with Foundation Models

23

Resetting Aberrant Tregs Epigenetically to Treat Autoimmune Diseases

24

Finding a Ready Treatment for a Newly Discovered, Ultra-Rare Disease

25

One Rare Mother’s Quest to Rewrite Her Son’s Future with a Gene Therapy

26

Transforming TSC Epilepsy with a Precision Therapy

27

Bridging the Valley for Rare Disease Drug Development

28

Turning a Rare Cancer into a Call to Action

29

Developing a New Approach to Cystic Fibrosis to Improve Outcomes

30

Finding Strength in Weakness

31

Developing Targeted Therapies for a Rare Autoimmune Disease

32

A Venture Fund that Leverages Patient Experts to Target Autoimmune Diseases

33

Navigating Your Child’s Rare Disease

34

Changing a Treatment Landscape by De-Risking Drug Development

35

Transforming Real-World Patient Data into Breakthroughs

36

Taking Aim at Huntington’s Disease and Other Repeat Expansion Disorders

37

Learning to Be a Caregiver and Advocate

38

Improving Rare Disease Care through Partnerships

39

A Call on the FDA for Timely Reviews of Life-Saving Therapies for Rare Diseases

40

The Need to Look Beyond Seizures When Treating DEEs

41

Taking On Big Competitors with an Oral Therapy to Treat Achondroplasia

42

Going Viral to Fight Brain Cancer

43

Changing the Playbook on Childhood Cancers

44

Sometimes the Hoofbeats Do Belong to Zebras

45

Breathing Easier with a Breakthrough Immunotherapy

46

Using AI Open Innovation to Tackle ALS

47

Recovering What’s Lost in Translation

48

Targeting Hunger Rather than Appetite in Prader-Willi Syndrome

49

A Rare-to-Common Business Model

50

Leading a Rare Youth Movement

51

Developing Gene Therapies that Work Across Mutations

52

Eyeing A Challenge to a Blockbuster

53

Like Mother, Like Child

54

Transforming from Grandmother to Mother to Advocate

55

Overcoming a Delivery Challenge of Retinal Gene Therapies

56

A Gene Editing First Augurs an Era of Bespoke Therapies

57

How One Patient Organization Drives Drug Development

58

Using CRISPR to Modulate Gene Expression

59

Satisfying the Hunger for a Prader-Willi Therapy

60

How an Academic Medical Center Helped Change the Landscape for a Rare Disease

61

Improving Outcomes for People with a Set of Rare Cancers

62

An Effort to Build a Better DMD Gene Therapy

63

A Once-Failed Pain Therapy Shows Potential in a Neurodevelopmental Disorder

64

Advancing a Cutting-Edge Therapy for a Rare, Childhood Cancer

65

Learning to Take His Vitamins

66

The First Treatment for a Rare Neurodegenerative Condition Awaits FDA Approval

67

Engineering Skin Bacteria to Be Live Biotherapeutics

68

Seeing the Gene and Cell Therapy Translational Divide as an Opportunity

69

My Mother, Myself, and ALS

70

From Immovable Object to Advocacy Force

71

A Rapid and Scalable Approach for Screening Personalized ASOs

72

Addressing the Disease Mechanism of a Rare Kidney Disease

73

The Mother of a Son with SCD, Applies Direct Experience to Her Clinical Trials Work

74

A First for Rett Syndrome with More in the Pipeline

75

A Heart Attack that Led to a Rare Disease Diagnosis

76

Targeting Rare Liver Diseases with Gene Editing Therapies

77

Using AI to De-Risk Rare Disease Drug Development

78

Addressing a Growing Demand for Plasma-Derived Therapies

79

Empowering Patients with Data to Drive Drug Development

80

How Advocates Are Advancing a Treatment for an Ultra-Rare Disease

81

Engineering B Cells to Produce Therapeutic Proteins

82

A Pipeline Win as BridgeBio Learns to Balance Theory with Practice

83

Considering What It Will Take for Payers to Embrace Advances in Sequencing

84

Finding Strength

85

A Non-Profit Works to Advance a DMD Gene Therapy

86

Accepting What We Can’t Understand

87

A Gene Therapy Company Born from a Father’s Efforts to Save his Daughter

88

Lowering Barriers to Clinical Trial Participation with Do-It-Yourself Blood Sample Collection

89

Scaling N-of-1 Therapies to Viability

90

Building Gene Therapies that Address Gain and Loss of Function Simultaneously

91

How One Woman Climbed from Patient to Advocate

92

Shortening the Diagnostic Odyssey

93

Making Exomes More Revealing

94

How One Patient Organization Catalyzed Drug Development

95

Enabling On-Demand Therapies

96

After Driving an N-of-1 Therapy for Her Son, an Advocate Turns to Helping Others

97

Putting Rare Disease Organization in the Business of Drug Development

98

Understanding the Many Questions Gene Therapies Raise

99

A Test to Identify People Likely to Develop ALS

100

How an Ultra-Rare Disease Patient Foundation Advanced a Gene Therapy

101

Making the $10 Genome a Reality

102

A No-Nonsense Effort to Develop a Therapy that Works Across Genetic Diseases

103

Mapping a Perilous Journey with Humor

104

Restoring Vision in Inherited Retinal Disease

105

Bringing Genome Sequencing to Rural Populations

106

Addressing a Blind Spot in Treatments for the Cornea

107

Taking a Different Approach to Rare Epilepsies

108

A Rare Disease Drug Developer Tries to Earn Its Stripes

109

Using Plasma to Treat Rare Diseases

110

Differentiating Gene Therapies through Regulatory Elements

111

How One Patient Organization Leverages Research Investments

112

Charging into the Storm

113

A Gene Therapy Developer that Embraces Different Models for Reaching Patients

114

Using Directed Evolution to Develop New Vectors for Genetic Medicines

115

Addressing a Shortage of Genetic Counselors with AI

116

A Small Molecule Therapy to Regenerate Muscle in People with DMD

117

Forging a Faster Path for Gene Therapies

118

Determining the Value of Rare Disease Therapies

119

Buying and Building a Gene Therapy Presence

120

A Clinical Trial Failure Derails a Promising Technology

121

Helping People with Undiagnosed Rare Diseases Find Answers

122

Speeding and Scaling the Development of Genome Editing Therapies

123

Getting a Next-Generation Genome Editing Therapy for Sickle Cell Disease Back on Track

124

Trying to Break a Leg in a Wheelchair

125

A Drug Developer that Makes Pediatric Cancers a Priority

126

Harnessing the Body’s Natural RNA Machinery to Treat Diseases

127

Targeting the Leading Cause of Death in Friedreich’s Ataxia with a Gene Therapy

128

How Inhaled mRNA May Help Rare Disease Patients Breathe Easier

129

Changing What’s Possible with Cell and Gene Therapies

130

Why Flying with a Wheelchair Is a Civil Rights Issue

131

Mapping Spheres of Influence

132

Bringing Precision to the Treatment of Rare Cancers

133

The Challenges of Developing a Therapy for Pregnant Women with A Rare Condition

134

How One Drug Developer Is Addressing Health Inequities

135

Accelerating the Development of Genetic Medicines with AI

136

Leveraging AI to Address the Neuropsychiatric Conditions Associated with a Rare Disease

137

In Pursuit of a Treatment for His Son, A Lawyer Becomes a Biotech Executive

138

In Push for Treatment, a Patient Organization Becomes a Trial Sponsor

139

Delayed Diagnosis of Rare Diseases Takes Staggering Economic Toll

140

A Cell Therapy to Control Heart-Damaging Inflammation in Duchenne

141

Stimulating the Growth of Muscle Mass in People with Neuromuscular Diseases

142

Turning Grief into Action

143

A Plea to the FDA to Give an Ultra-Rare Disease Drug a Fair Hearing

144

How the Woolly Mammoth Beat a Path to Better Gene Therapies

145

A Genetic Counselor’s Journey into Patient Advocacy

146

A Company in the Fold of Rare Disease

147

Disabling Antibodies that Drive Rare, Immunological Conditions

148

Keeping the Sentinels of the Brain Vigilant

149

Considering the Unfinished Work in Cystic Fibrosis

150

How to Advocate for Yourself as You Battle Cancer

151

Targeting Neuroinflammation to Treat ALS

152

Leveraging Community Partnerships to Address a Rare Disease Behind a Medical Mystery in New Mexico

153

Accelerating Gene Editing Therapies for Rare, Neurological Conditions

154

Inhibiting Electrical Activity in Rare, Seizure Disorders

155

Improving the Function and Usability of Clothing for People with Disabilities

156

Treating Cardiopulmonary Disease with Inhaled Targeted Therapies

157

A Patient-Driven Registry Focused on Health-Related Quality of Life Data

158

An Ally for the Undiagnosed Emerges

159

Help for Rare Disease Patients That’s Just a Click Away

160

Diagnosing Autism with a Single Strand of Hair

161

Bringing Regenerative Medicine to a Rare Bone Condition in Children

162

Bringing Precision to CRISPR-Based Genome Editing

163

Capturing Patients’ Experience in Their Daily Lives

164

From One to Many

165

A Nasal Spray to Curb Excessive Eating in Prader-Willi

166

How One Foundation Is Laying the Groundwork to Advance Treatments for an Ultra-Rare Disease

167

Forging a New Path for Medicine

168

Restoring Hearing through Gene Therapies

169

Creating a Sustainable Reimbursement Model for Ultra-Rare Therapies

170

Lumos Hopes Its Oral Alternative to HGH Will Fuel Its Growth

171

Advancing a Gene Therapy for a Rare and Fatal CNS Disorder

172

Addressing the Barriers to Patient Participation in Clinical Trials

173

A Venture Philanthropist Makes the Case for Advocates Taking Equity

174

Seeking a Sustainable Business Developing on N-of-1 Therapies

175

How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition

176

A Next-Generation RNA Therapy Targets Telomere Disorders

177

BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families

178

Translating Urgency into Science

179

Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments

180

Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X

181

An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty

182

Powering Cells in People with Rare Mitochondrial Diseases

183

Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy

184

Developing a New Class of Therapies Based on a Natural Cargo Carrier

185

Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies

186

One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia

187

Treating Rare Endocrine Disorders with Therapeutic Peptides

188

Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases

189

Addressing the Current Limitations of AAV Gene Therapies

190

Examining the Legislative Landscape for Rare Disease Drug Development

191

How a Drug Setback Became a Patient Community’s Gain

192

Helping Regulators and Drug Developers Understand the Challenges of Living with Fabry Disease

193

Addressing Racial Disparities in a Rare Blood Cancer

194

How New Sequencing Technology Promises to Alter the Diagnostic Odyssey

195

Leveraging Technology to Empower Patients and Decentralize Clinical Trials

196

Equipping The Next-Generation Rare Disease Patient Advocate

197

How a Family Raced from Diagnosis to Experimental Gene Therapy in Three Years

198

How One Advocate Went from Losing His Hearing to Being Heard

199

Building a Pipeline of Therapies to Treat Rare Mineralization Disorders

200

Advancing an Oral Alternative to Infused and Injected Therapies for HAE

201

Embracing the Promise of Patient-Centered Biotechnology

202

Learning to Live with Loss

203

Using Cryptocurrency to Tap into the Wisdom of Crowds

204

A Therapy for a Rare Neurodegenerative Disease Moves Towards Regulatory Review

205

Transforming the Treatment of Neuromuscular Diseases with Next-Gen Oligonucleotides

206

Teaching the Immune System to Let Medicines Do Their Job

207

Designing Clinical Trials with the Patient in Mind

208

Keeping Clinical Trials Running Smoothly

209

A Vision for Patient-Centric Gene Therapy Development

210

Using Genetic Testing to Address Disparities in Care for Kidney Disease

211

Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development

212

A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company

213

Targeting Regulatory RNA to Upregulate Gene Expression to Treat Rare Diseases

214

Developing a New Approach to Treat Rare, Autoimmune Conditions

215

Bridging the Gap Between Basic and Commercial Research for Rare Disease

216

Stoking Functional Copies of Genes to Compensate for Mutated Ones

217

Targeting ALS with Synergistic Combinations of Therapies

218

How a Polish Rare Disease Organizations Is Helping Its Ukrainian Neighbors

219

Powering a New Era of Genetic Medicine

220

Searching for a Diagnosis

221

A Novel Way to Deliver Rare Disease Therapies

222

Bringing Diversity, Equity, and Inclusion to the Books We Read

223

From Mila to Millions: Scaling N of 1 Therapies

224

Genetically Modifying Patients’ Skin Cells to Treat Rare Diseases

225

Targeting Rare, Immunologic Disorders

226

Harnessing a Natural Mechanism to Silence Disease

227

Advancing Precision Medicine with Patient Data

228

Pregnancy and Motherhood for a Woman with SMA

229

Steps to Improve Data Gathering of Rare Diseases

230

Rare Patients Learn to Make Their Voices Heard

231

Empowering Patient Organizations with Real-World Data

232

A Healthcare Communications Student Gets an Education as a Patient

233

Expanding the CRISPR Toolkit

234

Marrying Antibodies to RNA Therapies to Target Previously Inaccessible Tissues and Cells

235

Expanding Access to Whole Genome Sequencing Across the Globe

236

A First-in-Class Approach to Treating a Rare and Chronic Liver Disease

237

A New Approach to Treating a Rare Endocrine Disorder

238

Detecting Genetic Disease Prior to Birth

239

Turning Words into Action: Equity, Diversity, and Inclusion in Rare Disease

240

Chasing Cures

241

A Map to Navigate A Rare Disease

242

A Popular Cancer Target Is Eyed for a Rare Immune Disorder

243

Leveraging a Gene Therapy Approach to Maximize Speed and Minimize Costs

244

Programing the Body to Make Its Own Medicine with Gene Therapy

245

Developing in Vivo Gene Editors that Target Liver Diseases

246

A Find-and-Replace Approach to Fixing the Mutation Underlying Sickle Cell Disease

247

A Bet on a Unique Set of Vectors

248

How a Rare Diagnosis Impacts a Family

249

Transforming the Rare Disease Landscape with Data

250

Creating a Playbook for Bespoke Gene Therapies

251

Finding Answers for Undiagnosed Patients with Rare Genetic Diseases

252

How a Familiar Face Can Lead to a Rare Disease Diagnosis

253

Bringing the Trial to the Patient

254

Targeting Rare and Chronic Kidney Diseases

255

Addressing the Delivery Challenges of Genetic Medicines

256

Targeting Tissues Throughout the Body with RNA Therapies

257

Delivering Rare Disease Therapies to Patients in Need

258

An Advocate's Journey through Diagnosis, Loss, and Hope

259

Using Model Systems to Find Drugs to Repurpose for Rare Diseases

260

How a Small and Young Foundation Catalyzed Research into a Rare Disease

261

Overcoming the Limitations of Conventional Cell Engineering

262

Experimental Therapy for Rare Endocrine Disorder Offers Hope of Improved Care

263

Forging Gene Therapy Capacity and a Pipeline at the Same Time

264

Using A Natural DNA Repair Process to Improve Genetic Medicines

265

Empowering Rare Disease Patients with their Own Health Records

266

Targeting CNS Disease with Gene Therapies

267

A New Therapy Offers A Different Approach to Inhibiting the Complement System

268

Bringing Aberrant Proteins Back into the Fold

269

A Cat who Curates Rare Mice

270

Putting the Patient at the Center of Rare Disease Clinical Trials

271

Creating a Toolkit to Accelerate the Development of Gene Editing Therapies

272

PTC Looks to Advanced Therapies

273

Going to Extreme Lengths

274

Everything’s up to Date in Kansas City, at Least When It Comes to Genomics

275

Choosing the Right Viral Vector for a Gene Therapy

276

A Software Platform to Give Patients the Tools to Build Treatments for Rare Genetic Diseases

277

Side Effects: The Toll a Rare Disease Can Take on a Family in Pursuit of a Cure

278

Realizing the Potential of CRISPR Gene Editing

279

Understanding the Economic Toll of Rare Disease in the United States

280

The Promise of Gene-Based Therapies for Neurodegenerative Conditions

281

Moving Beyond Viral Vectors for Gene Therapies

282

Acquisitions Help Jazz Build Toward Commercial Crescendo

283

Powerful Gene Editing Approach Offers the Promise of Correcting a Range of Rare Diseases

284

A Child's-Eye-View of Clinical Trials

285

Using Nanoliposomes to Make Cancer Therapies Safer and More Effective

286

Accelerating Treatments for Rare Disease through Data Sharing

287

Treating the Root Cause of Sickle Cell Disease

288

Targeting a Common Pathway in Genetic Forms of Obesity

289

After Pruning Orchard, Gaspar Focuses on High Value Opportunities

290

Writing a New Chapter of Genetic Medicine

291

How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment

292

With a New Identity, Travere Thearpeutics Seeks to Find Its True Path

293

Making Gene Therapies Accessible to Patient with Ultra-Rare Conditions

294

Using RNA Therapies to Target Inherited Retinal Diseases

295

Part 4-Gene Therapy: A Researcher’s Perspective

296

Part 3-Gene Therapy: An Industry Perspective

297

Part 2-Gene Therapy: A Patient Advocate's Perspective

298

Part 1-Gene Therapy: A Genetic Counselor’s Perspective

299

An App to Make Patients the Experts in their Own Conditions

300

Pursuing a New Target for Autoimmune Diseases

301

Finding a Rare Friend

302

Industrializing Individual Therapies for People with Rare Conditions

303

Rare Disease Advocate Turned Filmmaker Turns Lens on his Son

304

Inhibiting Signaling that Drives Growth of Rare Malformations

305

Readying a Rare Disease Community for the Availability of Treatments

306

Forging a Rare Disease Research Agenda

307

Delivering Injectable Drugs Orally

308

What Young Adults with Rare Conditions Need to Know About Health Insurance

309

Mirum Prepares to Seek Approval for Rare Liver Disease Therapy

310

Payer Perceptions of Fairness in Pricing Rare Disease Therapies

311

Improving Narcolepsy Therapy with Drug Delivery Technology

312

Fighting the Persistent Cough in a Rare and Deadly Lung Disease

313

Targeting Huntington's Disease with Antisense

314

Assembling a Pipeline for Rare GI Disorders

315

Treating Huntington's Disease by Addressing Neuroinflammation

316

How Patient Advocate-Led Research Can Alter a Rare Disease Landscape

317

Keeping Clinical Trials Going During a Pandemic

318

Looking for Commonalities in Rare

319

Learning to Be Comfortable Being Uncomfortable

320

An Approach to De-Risk Rare Disease Drug Development

321

Targeting Epigenetics in Rare Proliferative Bone Marrow Cancers

322

Chiesi Charges Ahead in Rare Disease

323

Targeting the Metabolism of Rare Cancers

324

Unlocking Bryson's Brain

325

Living Therapies for Chronic Conditions

326

A One-to-Many Approach to Gene Therapy for Retinal Disease

327

Targeting an Immune Switch in Rare Diseases

328

Targeting the Regulatory Genome to Treat Rare Blood Diseases

329

A Reborn Forma Therapeutics Focuses on Rare Blood Diseases and Cancer

330

Targeting Genetic Diseases at Their Root Cause

331

Targeting Hormone Dysregulation in Prader-Willi Syndrome

332

Rare Disease Advocates Take to the Hill

333

Targeting a Common Link in Otherwise Different Rare Diseases

334

Bringing Clinical Trials to Patients

335

Crowdsourcing Therapeutic Approaches for an Ultra-Rare Disease

336

Delivering Oligonucleotide Therapies to Any Cell Type

337

Protalix Looks Beyond Biobetters

338

Driving N-of-1 Therapies for Ultra-Rare Disease Patients

339

Cutting the Time and Cost of Drug Discovery with MicroOrgans

340

Acquisition Combines Two Pipelines for Rare Skin Diseases

341

Programming Cells to Produce Neuroprotective Factors to Treat ALS

342

Origin's Rapid Path to Seek Approval for Treatment of Ultra-Rare Metabolic Condition

343

Developing a Common Language for Rare Diseases

344

Why Payers Lag Drug Developers and Regulators in Embracing Real-World Evidence

345

How a Brother's Love Is Forging a Path for Customized Therapies for Rare Disease Patients

346

Addressing the Barriers to Accessing Experimental Therapies

347

A Journey to Advocacy

348

Turning Chronic Illness into a Fashion Statement

349

Connecting Young Adults with Rare and Chronic Conditions

350

Helping Caregivers Care for Themselves

351

A Festival of Moving Pictures

352

Deep Genomics Boasts an AI First in Drug Discovery

353

How to Live with a Disability with Your Mojo Intact

354

Why a Big Pharma Exec Embraced Rare Neurological Diseases

355

Fighting for Other People's Children

356

A Doctor's Quest to Cure His Own Rare Disease

357

Susannah Cahalan and her Month of Madness

358

The Benefits Support Groups Offer Rare Disease Patients

359

Targeting the Epigenetic Drivers of Cancer

360

Tackling Kidney Diseases with Orally-Delivered Enzymes

361

Giving Voice to Patients through Data

362

Seeking to Halt and Reverse Fibrotic Diseases

363

Addressing the Complexities of Rare Disease with Centers of Excellence

364

Using Cell Therapies to Restore Power in Mitochondrial Diseases

365

Passage Bio Betting on Penn Connection to Give It an Edge in Developing Gene Therapies

366

Finding Appropriate Endpoints and Measures for Rare Eye Diseases

367

Marrying Antibodies and Oligonucleotides to Target Genetic Medicine

368

What Rare Disease Patients Should Understand about Genetics

369

Program Seeks to Drive Collaborative Research Model Among Rare Disease Groups

370

A Gene Hunter Becomes a Drug Hunter Too

371

The Psychological Toll Rare Diseases Can Have on Healthy Siblings

372

Blood Test Can Provide Earlier Diagnosis of Autism Spectrum Disorder

373

Understanding the Role of Natural History Studies in Clinical Trials

374

How Two Mothers Discovered That a Drug for One Rare Disorder Might Benefit Another

375

Shortening the Diagnostic Odyssey

376

Eliminating Barriers to Adoption of Children with Rare Diseases

377

A Young Rare Disease Advocate Discusses Life with an Undiagnosed Condition

378

The Benefits of an Open-Source Registry for Rare Diseases

379

How a Patient Group Helped Drive Drug Development in Rett Syndrome

380

How Misperceptions Can Create Barriers to Care

381

Targeting Repeat Expansion Disorders with Next-Gen Antisense Drugs

382

Getting Misfolding Proteins to Shape Up

383

A Different Approach to Inhibiting the Complement System

384

Looking Back in Time to Find Rare Disease Patients Today

385

Ionis CEO Stanley Crooke Discusses Success as a Platform Technology Company

386

Orchard Looks toward Harvesting Expanded Gene Therapy Pipeline

387

Connecting Rare Disease Patients in India and the United States

388

Regenerative Medicine Moves into the Spotlight

389

Learning New Tricks from Pathogenic Bacteria to Target the Microbiome

390

Orphan Drug Accelerator Spin-Out Tackles Rare Endocrine Disorders

391

Aspa Therapeutics Forges Gene Therapy for Rare Neurological Condition

392

How Patient-Led Collaborations Are Transforming Rare Disease Drug Discovery and Development

393

Sobi Expands Its Immunology Franchise with HLH Drug Approval

394

Learning to Thrive

395

Late-Stage Trial Underway for Treatment of Rare Obesity Disorder

396

RegenxBio Bets Its Gene Therapy Technology Provides Competitive Edge

397

The Potential for Digital Health Technologies to Transform Clinical Trials

398

Matching Volunteers to Rare Disease Organizations in Need

399

How One Rare Disease Organization Used Technology to Provide Greater Patient Insight to FDA

400

The Potentially Deadly Consequences of an Oversight in Newborn Screening Tests

401

Advancing a New Approach to Sickle Cell Disease

402

Conquering Life with a Rare Disease

403

Why Rare Disease Drug Developers Need Regular Interaction with the FDA

404

Making the Case for an FDA Rare Disease Center of Excellence

405

An Elite Runner Makes a Cross-Canada Trek for His Son and Rare Disease

406

How Rare Disease Advocates Can Get The Most out of Collaborations

407

Establishing Clinical Standards for a Rare Disease

408

Teen Rare Disease Advocate Fights the Condition That Took His Brother's Life

409

Addressing the Emotional Toll of Rare Diseases

410

Forging a Research Agenda for a Rare Disease

411

Living with an Uncertain Rare Diagnosis

412

A Rare Disease Advocate Teaches Doctors to See and Speak Differently

413

The Caregiver Who Cried in the Shower

414

Curating Patient Data to Accelerate Rare Disease Drug Development

415

Forging a Research Agenda for a Rare Disease

416

Making the Journey from All-American Athlete to Rare Disease Advocate

417

How Destiny Lamonte Learned to Advocate for Herself and Others

418

Where the NIH Does Its Banking

419

Making Sense of Nonsense Mutations

420

Rewriting Faulty RNA

421

Experimental Drug for "Elephant Man" Disease May Benefit Certain Cancers Too

422

Programming Stem Cells to Protect Neurons in ALS and other Neurodegenerative Conditions

423

Why a Topical, Off-the-Shelf, Gene Therapy May Hold Promise for a Rare Skin Condition

424

An Ironman Champion with Cystic Fibrosis Discusses her Changing Relationship with Her Disease

425

Why an Experimental Fragile X Drug May Treat a Range of Neurodegenerative Diseases

426

The Case for a Daily Self-Injection to Treat Hemophilia

427

Addressing the Challenges of R&D for Rare Cancer Therapies

428

Learning to Communicate and Collaborate as a Patient Advocate

429

Seeking Answers for Undiagnosed Patients

430

When "Undiagnosed" Is Your Diagnosis

431

The Decision to Get Tested for Huntington's Disease and How It Changed Seth Rotberg's Life

432

Nonprofit Sees Need in Developing Gene Therapies for Inherited Eye Disesases

433

Casting a Wider Net for Genetic Diseases

434

Corbus Seeks to Quiet the Immune System in Chronic Conditions

435

Addressing the Challenges of Rare Disease Drug Development

436

Giving Voice to Patients at the FDA

437

Finding a Rare Friend

438

Why a Sports Physical May Trigger a Doctor to Think About a Rare Diagnosis

439

UPenn's Orphan Disease Center Takes a Rare Approach

440

How Patients Can Accelerate Translational Research in Rare Disease

441

Notre Dame Center Leverages Commonalities of Rare and Neglected Diseases

442

GalXC Quest: Dicerna Bets on Its Unqiue Approach to RNAi

443

Pharnext Takes a Unique Twist on Repurposing Drugs for Rare Diseases

444

uniQure Seeks to Find Elusive Market Success with Hemophilia B Gene Therapy

445

Savara Advances Pipeline of Inhaled Therapeutics for Rare Lung Diseases

446

Why the Microbiome May Provide a Novel Approach to Treating Certain Rare Diseases

447

FDA Outlines a Collaborative Approach for Pediatric Rare Disease Trials

448

Why Patient-Centred Outcomes Are Critical to Rare Disease Drug Trials

449

What the FDA's New Framework Means for Regenerative Therapies

450

Measuring the Value of Therapies for Ultra-Rare Diseases

451

Lessons from Pitching Venture Capitalists

452

Health Canada Scraps Plans for Orphan Drug Framework

453

New Investment Boosts Rare Disease Drug Accelerator

454

Understanding Rare Disease Caregiver Needs

455

Deriving Rare Disease Therapies from Human Plasma

456

Learning to Live with Purpose

457

A Mother's Race to Find a Treatment for Her Daughter's Ultra-Rare Condition

458

Screening for Rare Diseases

459

A Look at the Changing World of Work for People with a Chronic Illness

460

Aligning Interests in Rare Disease Partnerships

461

A Veteran Venture Capitalist Discusses Investing in Rare Disease Drug Development

462

A Patient Group Crafts Guidelines for Working with Pharma

463

Bringing Innovation to Business Models for Rare Disease Drug Development

464

Rethinking Accessibility and Dependency

465

How Simon Wheatcroft, Blinded by a Rare Disease, Became an Ultramarathoner

466

Spark Hoping Its Luxturna Will Become First FDA-Approved Gene Therapy

467

What Rare Patient-Investors Can Learn From Venture Capitalists

468

Novel Effort Delivers Failed DMD Drug to Former Clinical Trial Participants

469

Centogene Seeks to Deliver Diagnoses to Rare Disease Patients Early

470

Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases

471

aTyr Pharma Seeks to Modulate Activity in FSHD and Other Rare Disease

472

Summit Pursues A Different Approach to Treating Duchenne

473

Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier

474

Sangamo Advances Gene Editing Therapies for Multiple Rare Diseases into the Clinic

475

Navigating the Challenges of Rare Disease Drug Development

476

Accelerating Rare Disease Drug Discovery

477

Experimental Rare Disease Therapy Wins New FDA Reg Med Designation

478

How Rare Disease Patients Can Get their Voices Heard in Drug Discovery and Development

479

One Patient's Difficult Road to a Rare Diagnosis

480

How Researchers Diagnosed Four Patients with a Never-Before-Identified Rare Disease in a Day

481

Stem Cell Gene Therapy Restores Immune System in Kids with SCID

482

Rare Disease Advocates Push for Incentives to Drugmakers Pulled from Cures Act

483

Non-Profit Drug Company Seeks to Advance Rare Disease Therapies

484

Innovative Collaboration Model Drives Treatment for Rare Disease

485

Girl with Rare Disease Inspires Search for Bone Marrow Donors

486

A Quest for Tribe: Searching for Others with the Same Ultra-Rare Mutation

487

Raising Awareness in a Town with a History of a Rare Disease

488

Helping Rare Disease Patients Navigate the World of Information

489

Overcoming the Challenges of Rare Disease Drug Development

490

Moving Rare Disease Therapies from Hope to Reality

491

Children’s National Launches First-of-its-Kind Rare Disease Center

492

A Common Link in a Group of Rare Diseases Creates an Opportunity for Repurposing

493

Sobi Works to Expand Rare Disease Indications for Its Drugs

494

Why Rare Disease Patients Should Work Together to Address Common Concerns

495

Solving Medical Mysteries with the Wisdom of Crowds

496

Embracing Collaborations to Drive Development of Rare Disease Therapies

497

Determining If a Child's Neurologic or Psychiatric Symptoms are Caused by an Infection

498

Helping Patients with the Same Undiagnosed Genetic Condition Find Each Other

499

An Entrepreneur Uses a Silicon Valley Approach to Tackle Rare Disease

500

Looking for Love with a Rare Disease

501

Why Genomics May Be in Google's DNA

502

The Power of Small Grants to Make Big Impacts

503

Building an International Registry for Rare Diseases

504

Discovering the Creative Use of Outrage

505

Diagnosing Rare Diseases with Facial Analysis

506

Charles River Sees Opportunity in Fostering Rare Disease Collaborations

507

Abeona Advancing Pipeline of Gene Therapies for Rare Diseases

508

A Patient Attends "an Academic Conference for Everyone"

509

Teen Advocate Preaches Message of Kindness

510

A Controversial Approval for a Duchenne Drug and What's Ahead

511

Matchmaker Exchange Helps Rare Disease Community Find Me a Find

512

The Promise of RNAi for Hereditary Angioedema and Other Rare Diseases

513

Why Natural History Studies Matter to Rare Disease Patients

514

Harnessing Big Data to Work for Rare Disease Patients

515

Lessons from Autism on Accelerating Drug Development

516

How One Rare Disease Group Leverages Relationships with Industry

517

Ice Bucket Challenge Begins to Yield Results

518

Why a Common Diabetes Drug May Be Able to Treat a Rare Disease

519

How to Improve Patient Access to Experimental Drugs

520

Using Social Media to Find Rare Disease Patients for Clinical Trials

521

How Rare Disease Patients Weigh Risks and Benefits of a Therapy

522

Why Homology Medicines Might Be a Game Changer for Gene Therapy

523

Orchard Hopes to Bear the Fruit of Gene Therapy

524

Novel Approach to Treat Rare Disease May Lead to Drugs for Common Ones

525

Brining Whole Genome Sequencing into the Clinic

526

Bringing Patient-Centricity to Clinical Trials

527

Determining If a Child's Neurologic or Psychiatric Symptoms are Caused by an Infection

528

Making Genetic Data Accessible to Researchers

529

How New Sequencing Technology Is Changing Our Understanding of Rare Diseases

530

Marathon Readies DMD Drug for FDA

531

Searching for Genes They May Protect Against Deadly Diseases

532

Helping Patients with the Same Undiagnosed Genetic Condition Find Each Other

533

Living with a Disease in Search of a Name

534

New Means of Regulating Genes May Hold Promise for Rare Disease Patients

535

Invitae Seeks a Faster, Cheaper Path to Diagnosing Genetic Diseases

536

Filmmaker Turns Lens on the Rare Disease Community

537

The Case for Keeping Orphans Where They Can Thrive

538

Rare Disease Legislation Advancing at National, State Level

539

The Evolving Relationship Between Patient Advocates and Pharma

540

Phil Reilly on The Quest to Save Children with Rare Genetic Disorders

541

Unlocking the Genetic Mysteries of Rare Diseases

542

A Vision for Making Kansas City a Rare Disease Center of Excellence

543

A Push in Canada for a National Rare Disease Strategy

544

Jazzed in Utah for World Rare Disease Day

545

Group Aims to Accelerate Repurposing of Drugs to Treat Rare Diseases

546

Gene Therapies Bring New Hope to Rare Disease Patients

547

Why Rare Disease Research Should Matter to Everyone

548

Researchers Say Reform of the Orphan Drug Act is Needed

549

Looking for Love with a Rare Disease

550

Gene Editing Tool Holds Promise in Rare Disease Treatments

551

A Cross Country Quest for Marrow Donors

552

Building Strength by Sharing Stories

553

North Carolina Seeks Leadership Role in Combating Rare Diseases

554

The Power of Small Grants to Make Big Impacts

555

Tearing Down Differences with Film

556

Educating Docs to Improve Diagnosis and Treatment of Genetic Metabolic Diseases

557

Providing Young Adult Cancer Patients and Survivors Resources They Need

558

Gene Therapy Company Born from Mother's Quest to Cure Daughter

559

Accelerating Rare Disease Research through Collaboration

560

Cracking the Genetics of Rare Diseases through Crowdsourcing

561

Teen Advocate to World: "We are More than Our Diseases"

562

Why the 21st Century Cures Act May Be in Trouble in the Senate

563

How Lisa Bentley Became a World Class Triathlete with Cystic Fibrosis

564

Understanding the Rare Disease Caregiver

565

Addressing Life-Threatening Rare Diseases with Gene Therapy

566

Living with, Rather Than for, a Rare Disease

567

An Entrepreneur Uses a Silicon Valley Approach to Tackle Rare Disease

568

Chronicling the Genomic Revolution

569

How a Radio Personality Became a Rare Disease Advocate

570

Why Genomics May Be in Google's DNA

571

An FDA Perspective on Rare Diseases

572

Helping Patients Take Control of Their Healthcare

573

Living Life Beyond Limits

574

Noah Coughlan Completes His 3,000 Mile Trek for Rare Diseases

575

How the 21st Century Cures Act Puts Patients at the Table

576

Using Cell and Gene Therapies to Treat Rare Skin Diseases

577

Incentives Boost Innovation in Rare Disease Therapies

578

Tensions Brew Between Pharma and Patient Advocacy Groups

579

The Attraction of Being a Rare Disease Drug Company

580

Confronting Genetic Destiny in The Lion's Mouth Opens

581

Royal Pains Throws Spotlight on Rare Diseases

582

Making the Case Rare Diseases are Fundamental

583

Programming the Immune System to Produce Drugs

584

How One Everyday Superhero Combats Rare Disease

585

Terminally Ill Patients Find Hope in Utah's Right to Try Law

586

Discovering the Creative Use of Outrage

587

New Diagnostic Offers Fast Answers For Group of Rare Diseases

588

One Researcher's Effort to Address a Fundamental Challenge in Rare Disease Research

589

Turning Lights and Camera into Action: A Mom's Search for Answers

590

A Teenager's Transformation from Patient to Advocate

591

How the Orphan Drug Act Reshaped the Rare Disease Landscape

592

Why the OPEN ACT Could Greatly Expand Treatments for Rare Disease

593

Rare Disease Company Seeks 100 Drugs in 10 Years

594

A Run Across America to Raise Rare Disease Awareness

595

Tapping the Public to Keep Scientists Current on Rare Disease Research

596

Why Raising Awareness Matters in the Fight Against Rare Diseases

597

The First Lady's Date who Embodied Precision Medicine

598

Startup with NIH Deal Seeks to Speed Drugs for Rare Diseases

599

Expanding the Potential of Crowdfunding

600

A Father's Search to Cure His Son's Rare Disease

601

How Venture Philanthropy Can Accelerate Drug Development

602

How New Funding Models Are Accelerating Drug Development